<I>Candida</I>属および<I>Aspergillus fumigatus</I>によるマウス全身感染に対するmicafunginの防御効果

DOI 被引用文献8件 参考文献19件

書誌事項

タイトル別名
  • Efficacy of micafungin, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis

この論文をさがす

抄録

The efficacy of micafungin (MCFG), a novel water-soluble lipopeptide, was evaluated in mouse models of disseminated candidiasis and aspergillosis, and was compared with that of amphotericin B (AMPH-B), fl uconazole (FLCZ) and itraconazole (ITCZ). In the candidiasis model in mice with granulocytopenia induced by cyclophosphamide, MCFG significantly prolonged the survival of mice infected intravenously with Candida albicans at doses of 0.125mg/kg or higher (P<0.01). In candidiasis and aspergillosis caused by C. albicans, Candida glabrate, Candida tropicalis, Candida krusei, Candida guilliermondii and Aspergillus fumigatus, MCFG exhibited ED50 s in the range of 0.14-1.61 mg/kg. These data were comparable or inferior to those of AMPH-B, but superior to FLCZ and ITCZ. In disseminated candidiasis in mice immunosuppressed by cyclophosphamide, hydrocortisone or 5-fluorouracil, the ED50 s of MCFG were 0.14-0.33mg/kg, superior to ITCZ and FLCZ, but inferior to AMPH-B. In a target organ kidney assay, a single injection of MCFG at a doses of 0.5 or 1.0mg/kg significantly reduced the yeast viable cell counts in the kidney 24 hours after treatment compared to the yeast counts before treatment, with an efficacy comparable to AMPH-B. These results indicate that MCFG is a potent parenteral administered therapeutic agent for disseminated candidiasis and aspergillosis in immunosuppressed mice. The efficacy of MCFG was superior to that of FLCZ and ITCZ, but comparable or slightly inferior to that of AMPH-B.

収録刊行物

被引用文献 (8)*注記

もっと見る

参考文献 (19)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ